

MEDIA FACT SHEET

Prospera™ Spinal Cord Stimulation System

April 2023

Chronic intractable pain is a severe, constant, and debilitating pain that is not curable and cannot be relieved by ordinary medical or pharmaceutical measures. Unlike more common chronic pain, intractable pain causes adverse biologic effects on the body's cardiovascular, hormone, and neurologic systems. Approximately 100M US adults suffer from chronic pain.¹

Spinal cord stimulation (SCS) can be an effective treatment for chronic intractable pain, but often requires periodic adjustments and ongoing compliance to ensure therapy remains optimized. Most patients need help optimizing their SCS for adequate treatment. The current process requires patients to wait for that assistance until they can meet in person, often for prolonged periods of time, without optimized therapy. This can lead to rapid return of pain, increased difficulty managing pain, decreased quality of life, and a higher chance of therapy abandonment.^{2,3}

The current US SCS market is valued at approximately \$2B.⁴

- BIOTRONIK Neuro's Prospera™ is paired with Embrace One™, a proactive patient-centric care model offering automatic, objective, daily remote monitoring and ongoing management and support, seven days a week, for the lifetime of therapy.*

- Prospera features RESONANCE™, the first and only multiphase stimulation paradigm designed on how the body processes pain to deliver optimized relief. An advantage of this therapy is that it stimulates a broader area of nerves in the body.

With automatic, remote monitoring of a patient's therapy and SCS therapy support seven days a week, BIOTRONIK Neuro's solution is a truly proactive care model aimed at addressing these challenges.



References:

*Embrace One is a support platform intended to help manage a patient's experience with spinal cord stimulation. It is not intended to be used for medical diagnosis or medical treatment.

*Proactive Care: BIOTRONIK Neuro's remote support team may reach out to patients to ensure proper usage of the spinal cord stimulator based on remotely monitored data. BIOTRONIK Neuro does not provide health advice or clinical actions outside the scope of spinal cord stimulator proper usage. This product support is not a replacement for the patient's responsibility to communicate any medical questions or concerns to the physician's office.


1. Institute of Medicine (US) Committee on Advancing Pain Research, Care, and Education. Relieving Pain in America: A Blueprint for Transforming Prevention, Care, Education, and Research. Washington (DC): National Academies Press (US); 2011.

2. Amirdelfan K., et al. Health-related and economic impacts of clinic visit burdens for spinal cord stimulation patients and caregivers. Poster presented at: North American Neuromodulation Society Annual Meeting; January 12-15, 2023; Las Vegas, NV.

3. Amirdelfan K., et al. Rapid return of pain upon discontinuation of commercial spinal cord stimulation systems in patients with chronic pain. Poster presented at: American Society of Pain and Neuroscience Annual Conference; July 14-17, 2022; Miami Beach, FL.

4. SmartTRAK Financial Dashboard & Market Overview April 2023

BIOTRONIK at a Glance

At BIOTRONIK , patient well-being is our top priority and has been for more than 60 years. BIOTRONIK is a leading global medical technology company with products and services that save and improve the lives of millions suffering from heart and blood vessel diseases as well as chronic pain. BIOTRONIK is headquartered in Berlin, Germany, and is represented in over 100 countries.



Global Impact

Physicians have implanted more than 20 million BIOTRONIK devices in over 100 countries.



Business Areas

BIOTRONIK is active in cardiac rhythm management, electrophysiology, vascular intervention and neuromodulation.



R&D

BIOTRONIK is headquartered in Berlin and researches, develops and manufactures exclusively in the high-tech countries of Germany, Singapore, Switzerland and the United States.

All critical components are manufactured in-house to ensure uncompromised safety, the highest quality and reliability. One in five employees at Berlin headquarters work in research and development.

Find us on Social Media

